Clinical Trial Detail

NCT ID NCT04023669
Title Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors St. Jude Children's Research Hospital
Indications

medulloblastoma

Therapies

Filgrastim

Pegfilgrastim

Cyclophosphamide + Prexasertib

Gemcitabine + Prexasertib

Age Groups: adult child

No variant requirements are available.